Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Astrocytoma × Eflornithine × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 9 Neuroectodermal Tumors, Primitive 2 Medulloblastoma 2 Glioma 2 Typical Teratoid Rhabdoid Tumor 1 Sarcoma, Ewing 1 Rhabdoid Tumor 1 Osteosarcoma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 107 Radiotherapy 59 Carboplatin 28 Bevacizumab 28 Carmustine 26 Magnetic Resonance Spectroscopy 24 Filgrastim 20 Surgical Procedures, Operative 18 Irinotecan 18 Radiation 16 Lomustine 16 Vincristine 14 Etoposide 13 Specimen Handling 11 Radiotherapy, Intensity-Modulated 11 Procarbazine 11 Peripheral Blood Stem Cell Transplantation 11 O(6)-benzylguanine 11 Erlotinib Hydrochloride 11 Cyclophosphamide 11 sargramostim 10 Chemotherapy, Adjuvant 10 Cisplatin 9 antineoplaston AS 2-1 8 antineoplaston A10 8 Thiotepa 8 Granulocyte Colony-Stimulating Factor 8 Flucytosine 8 Everolimus 7 vocimagene amiretrorepvec 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡